TY - JOUR
T1 - Weekly 1-hour infusion of paclitaxel
T2 - Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma
AU - Trivedi, Charu
AU - Redman, Bruce
AU - Flaherty, Lawrence E.
AU - Kucuk, Omer
AU - Du, Wei
AU - Heilbrun, Lance K.
AU - Hussain, Maha
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2000/7/15
Y1 - 2000/7/15
N2 - BACKGROUND. Preclinically, paclitaxel given according to an intense bolus schedule has significant antitumor activity against human prostate carcinoma cell lines in SCID mice. The authors evaluated the feasibility and efficacy of weekly 1-hour infusion of paclitaxel in patients with metastatic hormone-refractory prostate carcinoma (HRPC). METHODS. A total of 18 patients with progressive metastatic HRPC were enrolled. Patients had to have no prior chemotherapy. Paclitaxel was infused weekly at a dose of 150 mg/m2 over 1 hour for 6 weeks every 8 weeks. RESULTS. Eighteen patients with a median age of 68.5 years and a median prostate specific antigen (PSA) level of 82 ng/mL (range, 2.17-3196 ng/mL) were enrolled. The median number of prior hormone treatments was 2, and 12 patients on antiandrogens completed antiandrogen withdrawal. Ten of eighteen patients had bone-only metastasis and eight had metastasis to bone with lymph node and/or visceral metastasis. Seventeen patients received a total of 31 cycles (157 courses) and 1 patient refused chemotherapy. All patients were included in response evaluation. Of the 18 patients with measurable disease, 4 achieved a major response, with 1 complete response (in the lung) and 3 partial responses (1 in the liver and 2 in the lymph nodes). Seven of eighteen patients (39%) had a PSA decline of ≥50%. The major high grade toxicity was peripheral neuropathy, with 6 patients (35%) developing Grade 3 toxicity. CONCLUSIONS. Weekly 1-hour paclitaxel has activity in patients with HRPC. The major toxicity is peripheral neuropathy. The minimal myelosuppressive effects make a modified schedule (lower doses on the same schedule or a shorter schedule of the same dose) attractive for future combination chemotherapy trials. (C) 2000 American Cancer Society.
AB - BACKGROUND. Preclinically, paclitaxel given according to an intense bolus schedule has significant antitumor activity against human prostate carcinoma cell lines in SCID mice. The authors evaluated the feasibility and efficacy of weekly 1-hour infusion of paclitaxel in patients with metastatic hormone-refractory prostate carcinoma (HRPC). METHODS. A total of 18 patients with progressive metastatic HRPC were enrolled. Patients had to have no prior chemotherapy. Paclitaxel was infused weekly at a dose of 150 mg/m2 over 1 hour for 6 weeks every 8 weeks. RESULTS. Eighteen patients with a median age of 68.5 years and a median prostate specific antigen (PSA) level of 82 ng/mL (range, 2.17-3196 ng/mL) were enrolled. The median number of prior hormone treatments was 2, and 12 patients on antiandrogens completed antiandrogen withdrawal. Ten of eighteen patients had bone-only metastasis and eight had metastasis to bone with lymph node and/or visceral metastasis. Seventeen patients received a total of 31 cycles (157 courses) and 1 patient refused chemotherapy. All patients were included in response evaluation. Of the 18 patients with measurable disease, 4 achieved a major response, with 1 complete response (in the lung) and 3 partial responses (1 in the liver and 2 in the lymph nodes). Seven of eighteen patients (39%) had a PSA decline of ≥50%. The major high grade toxicity was peripheral neuropathy, with 6 patients (35%) developing Grade 3 toxicity. CONCLUSIONS. Weekly 1-hour paclitaxel has activity in patients with HRPC. The major toxicity is peripheral neuropathy. The minimal myelosuppressive effects make a modified schedule (lower doses on the same schedule or a shorter schedule of the same dose) attractive for future combination chemotherapy trials. (C) 2000 American Cancer Society.
KW - Androgen- independent status
KW - Dose-limiting toxicity
KW - Hormone-refractory prostate carcinoma
KW - Weekly paclitaxel
UR - http://www.scopus.com/inward/record.url?scp=0034662046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034662046&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(20000715)89:2<431::AID-CNCR31>3.0.CO;2-B
DO - 10.1002/1097-0142(20000715)89:2<431::AID-CNCR31>3.0.CO;2-B
M3 - Article
C2 - 10918176
AN - SCOPUS:0034662046
VL - 89
SP - 431
EP - 436
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 2
ER -